FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225631574> ?p ?o ?g. }

• W4225631574 abstract "Since early 2020, the SARS-CoV-2 virus (COVID-19) has challenged the world and perturbed our healthcare systems [1]. People with type 2 diabetes (T2D) are known to be at a higher risk of becoming unwell following COVID-19 infection when compared with people who do not have T2DM [2]. Access to longitudinal general practice electronic health records for people has allowed a greater resolution of outcomes over time for those who have contracted COVID-19. From the start of the COVID-19 pandemic in early 2020, the monthly incidence of infection in populations has varied both between countries and within countries with a corresponding variation in mortality rate. Infection/mortality incidence has even varied at even higher resolution across counties and within cities. In this study, we have identified across a 13-month period (1 June 2020 to 30 June 2021), the relative likelihood of death each month for people previously diagnosed with T2D following confirmed COVID-19 infection. An understanding of what has happened in the past in relation to mortality from COVID-19 can inform what may happen in the future in relation to the reality of our coexistence with the COVID-19 virus. Anonymized data on 13 807 COVID-19-infected T2D individuals were extracted from the Greater Manchester Care (UK) Record (GMCR) Graphnet database [3]. This included more than 99% of general practice patient records across the GM conurbation. Death was defined as occurring following a positive COVID-19 test up to and including 30 June 2021. Each odds ratio refers to the odds of dying once infected by COVID-19 in a given month, compared to that in the month of July 2020. The majority of deaths occurred within 28 days of confirmation of COVID-19 infection. Using July 2020 mortality rate as the baseline (when infection rates were at their lowest in that year), for T2D individuals, the risk of dying following a recorded COVID-19 infection was comparable in January/February 2021 to that in July 2020 (Table 1), with a progressive decrease in the odds ratio of death from the start of 2021. From December 2020, the proportion of T2D individuals vaccinated against COVID-19 has steadily risen across GM for initially the first vaccination (86.18% by the end of June 2021) and then subsequently for the second vaccination (77.96% by the end of June 2021). A total of 1062 (7.7%) T2D people died during the follow-up period, following a confirmed COVID-19 infection. Table 1 - Mortality odds ratio each month (compared to July 2020) and cumulative proportion of type 2 diabetes individuals vaccinated from June 2020 to June 2021 Month OR (95% CI) % with first vaccine % with second vaccine Intercept 0.097 (0.059–0.149) 0 0 Jun 20 1.347 (0.77–2.422) 0 0 Aug 20 0.819 (0.435–1.551) 0 0 Sep 20 0.698 (0.411–1.225) 0 0 Oct 20 0.582 (0.365–0.976) 0 0 Nov 20 0.661 (0.413–1.11) 0 0 Dec 20 0.793 (0.486–1.352) 2.83 0.05 Jan 21 0.905 (0.57–1.513) 25.75 0.91 Feb 21 0.564 (0.333–0.987) 64.88 1.18 Mar 21 0.723 (0.399–1.33) 81.44 9.35 Apr 21 0.254 (0.083–0.64) 83.55 39.67 May 21 0.226 (0.074–0.57) 85.31 70.23 Jun 21 0.35 (0.149–0.764) 86.18 77.96 The odds ratio relates to the likelihood of death in any month compared with July 2020.CI, confidence interval; OR, odds ratio. The advent of treatment of unwell COVID-19-affected patients with dexamethasone has significantly reduced illness severity and mortality rates across the world [4]. While we are not in a position to ascribe causality, we propose that this may be a key determinant of the much reduced relative mortality rate in T2DM individuals after the first wave of the pandemic. The phenomena described here are likely also related to the accumulating benefits at a population level of the UK National Health Service-led COVID-19 vaccination programme [5] from December 2020 onwards, in relation to even the first vaccine dose. Winter 2020/2021 UK lockdown will also have an impact on COVID-19 infection rates. However, we have used the ratio of mortality rate vs. confirmed COVID-19 infection rates, so the effect of lockdown measures should therefore not materially influence our findings. Regarding limitations, our mortality data does not indicate clearly if T2D patients died of COVID-19 itself or COVID-19-related complications and specifically who, of those patients who died from December 2021 onwards, were actually vaccinated vs. those who were not. In addition, we have relied on recorded positive COVID-19 status in the GMCR. The full picture around attributable risk for patients with T2D in relation to mortality is yet to be clarified. In conclusion, in our survey, we describe that mortality in people with T2D was no higher in early 2021 compared with mid-2020 and that mortality rates decreased through 2021. The factors underlying this likely relate to the accrual of benefits to the UK population of the COVID-19 vaccination programme and the use of dexamethasone for many hospitalized patients with a COVID-19 infection. Hopefully, further medical and therapeutic interventions will continue to improve treatments and outcomes, even as new variants of COVID-19 emerge. Acknowledgements The work of D.A.J. and R.W. was funded by the National Institute for Health Research (NIHR) Greater Manchester Patient Safety Translational Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. A.H.H. led on writing the original draft and contributed to the methodology and conceptualization. D.J. led on formal analysis and helped to write the manuscript at all stages. N.C. assisted with data interpretation and with writing the manuscript. R.W. accessed and verified the underlying data, supported the analysis and contributed to writing the manuscript. M.S. supervised the formal analysis and data visualization while also helping to write the manuscript at all stages. G.D. contributed to data visualization and the drawing of conclusions as did K.B.-D. S.A., N.P., W.O. and J.M.G. contributed to the conceptualization, methodology and writing the manuscript. The data used in the analyses presented were obtained with the permission of the Greater Manchester Care Record Board and were fully anonymized before being made available to the investigators. Conflicts of interest There are conflicts of interest." @default.
• W4225631574 created "2022-05-05" @default.
• W4225631574 creator A5009872155 @default.
• W4225631574 creator A5010330353 @default.
• W4225631574 creator A5016584868 @default.
• W4225631574 creator A5017804509 @default.
• W4225631574 creator A5018107888 @default.
• W4225631574 creator A5020263487 @default.
• W4225631574 creator A5024127124 @default.
• W4225631574 creator A5037988440 @default.
• W4225631574 creator A5059494163 @default.
• W4225631574 creator A5075760256 @default.
• W4225631574 creator A5083538986 @default.
• W4225631574 date "2022-01-28" @default.
• W4225631574 modified "2023-09-26" @default.
• W4225631574 title "SARS-CoV-2, diabetes and mortality: month by month variation in mortality rate from June 2020 to June 2021" @default.
• W4225631574 cites W3024471844 @default.
• W4225631574 cites W4210642183 @default.
• W4225631574 doi "https://doi.org/10.1097/xce.0000000000000258" @default.
• W4225631574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35128338" @default.
• W4225631574 hasPublicationYear "2022" @default.
• W4225631574 type Work @default.
• W4225631574 citedByCount "1" @default.
• W4225631574 countsByYear W42256315742023 @default.
• W4225631574 crossrefType "journal-article" @default.
• W4225631574 hasAuthorship W4225631574A5009872155 @default.
• W4225631574 hasAuthorship W4225631574A5010330353 @default.
• W4225631574 hasAuthorship W4225631574A5016584868 @default.
• W4225631574 hasAuthorship W4225631574A5017804509 @default.
• W4225631574 hasAuthorship W4225631574A5018107888 @default.
• W4225631574 hasAuthorship W4225631574A5020263487 @default.
• W4225631574 hasAuthorship W4225631574A5024127124 @default.
• W4225631574 hasAuthorship W4225631574A5037988440 @default.
• W4225631574 hasAuthorship W4225631574A5059494163 @default.
• W4225631574 hasAuthorship W4225631574A5075760256 @default.
• W4225631574 hasAuthorship W4225631574A5083538986 @default.
• W4225631574 hasBestOaLocation W42256315741 @default.
• W4225631574 hasConcept C116675565 @default.
• W4225631574 hasConcept C121332964 @default.
• W4225631574 hasConcept C126322002 @default.
• W4225631574 hasConcept C134018914 @default.
• W4225631574 hasConcept C144024400 @default.
• W4225631574 hasConcept C149923435 @default.
• W4225631574 hasConcept C159047783 @default.
• W4225631574 hasConcept C179755657 @default.
• W4225631574 hasConcept C194828623 @default.
• W4225631574 hasConcept C2778334786 @default.
• W4225631574 hasConcept C2779134260 @default.
• W4225631574 hasConcept C3006700255 @default.
• W4225631574 hasConcept C3007834351 @default.
• W4225631574 hasConcept C3008058167 @default.
• W4225631574 hasConcept C44870925 @default.
• W4225631574 hasConcept C524204448 @default.
• W4225631574 hasConcept C555293320 @default.
• W4225631574 hasConcept C71924100 @default.
• W4225631574 hasConceptScore W4225631574C116675565 @default.
• W4225631574 hasConceptScore W4225631574C121332964 @default.
• W4225631574 hasConceptScore W4225631574C126322002 @default.
• W4225631574 hasConceptScore W4225631574C134018914 @default.
• W4225631574 hasConceptScore W4225631574C144024400 @default.
• W4225631574 hasConceptScore W4225631574C149923435 @default.
• W4225631574 hasConceptScore W4225631574C159047783 @default.
• W4225631574 hasConceptScore W4225631574C179755657 @default.
• W4225631574 hasConceptScore W4225631574C194828623 @default.
• W4225631574 hasConceptScore W4225631574C2778334786 @default.
• W4225631574 hasConceptScore W4225631574C2779134260 @default.
• W4225631574 hasConceptScore W4225631574C3006700255 @default.
• W4225631574 hasConceptScore W4225631574C3007834351 @default.
• W4225631574 hasConceptScore W4225631574C3008058167 @default.
• W4225631574 hasConceptScore W4225631574C44870925 @default.
• W4225631574 hasConceptScore W4225631574C524204448 @default.
• W4225631574 hasConceptScore W4225631574C555293320 @default.
• W4225631574 hasConceptScore W4225631574C71924100 @default.
• W4225631574 hasIssue "1" @default.
• W4225631574 hasLocation W42256315741 @default.
• W4225631574 hasLocation W42256315742 @default.
• W4225631574 hasLocation W42256315743 @default.
• W4225631574 hasLocation W42256315744 @default.
• W4225631574 hasLocation W42256315745 @default.
• W4225631574 hasLocation W42256315746 @default.
• W4225631574 hasOpenAccess W4225631574 @default.
• W4225631574 hasPrimaryLocation W42256315741 @default.
• W4225631574 hasRelatedWork W3009669391 @default.
• W4225631574 hasRelatedWork W3036314732 @default.
• W4225631574 hasRelatedWork W3176864053 @default.
• W4225631574 hasRelatedWork W3198183218 @default.
• W4225631574 hasRelatedWork W4200329650 @default.
• W4225631574 hasRelatedWork W4200515529 @default.
• W4225631574 hasRelatedWork W4205317059 @default.
• W4225631574 hasRelatedWork W4206669628 @default.
• W4225631574 hasRelatedWork W4382894326 @default.
• W4225631574 hasRelatedWork W3127156785 @default.
• W4225631574 hasVolume "11" @default.
• W4225631574 isParatext "false" @default.
• W4225631574 isRetracted "false" @default.
• W4225631574 workType "article" @default.